bluebird bio, Inc. announced that on January 31, 2022, Jessica Whitten, chief accounting officer and principal accounting officer of the Company provided notice of her resignation from bluebird effective upon the Company's filing of its annual report on Form 10-K covering the period ended December 31, 2021. Gina Consylman, bluebird's chief financial officer and principal financial officer will serve as interim principal accounting officer until Ms. Whitten's replacement is hired.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.07 USD | +4.90% | +5.94% | -22.46% |
May. 09 | Transcript : Bluebird bio, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 06 | Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.46% | 197M | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- BLUE Stock
- News bluebird bio, Inc.
- Bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer